Literature DB >> 10419425

Medical management of aldosterone-producing adenomas.

R P Ghose1, P M Hall, E L Bravo.   

Abstract

BACKGROUND: No data are available on the long-term medical management of aldosterone-producing adenomas.
OBJECTIVE: To demonstrate the efficacy of medical management of aldosterone-producing adenomas in terms of blood pressure and serum potassium concentration and to discuss morbidity associated with medical management.
DESIGN: Retrospective cohort study.
SETTING: Large tertiary care referral center. PATIENTS: 24 patients with documented aldosterone-producing adenomas who were treated medically for at least 5 years. MEASUREMENTS: Aldosterone excretion rate, plasma renin activity, and size and location of adenomas (by computed tomography). Blood pressure and serum electrolytes were measured at the time of diagnosis and last follow-up.
RESULTS: From the time of diagnosis to the time of last follow-up, systolic blood pressure decreased from 175 mm Hg to 129 mm Hg (95% CI for difference, 37.1 to 53.8 mm Hg) and diastolic blood pressure decreased from 106 mm Hg to 79 mm Hg (CI for difference, 20.8 to 33.9 mm Hg). Serum potassium concentration increased from 3.0 mmol/L to 4.3 mmol/L (CI for difference, 1.1 to 1.5 mmol/L).
CONCLUSIONS: Medical management of aldosterone-producing adenomas is a viable option for controlling blood pressure and serum potassium concentration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419425     DOI: 10.7326/0003-4819-131-2-199907200-00005

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  27 in total

Review 1.  Medical management of primary hyperaldosteronism.

Authors:  E L Bravo
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

2.  [A 58-year-old hypertensive patient with primary hyperaldosteronism and renal artery stenosis].

Authors:  Michael Nguyen Quang; Bernd Krüger; Christopher D Krüger; Andreas Walberer; Bernhard Schenck; Klaus Kisters; Martin Wenning; Bernhard K Krämer
Journal:  Med Klin (Munich)       Date:  2010-04

Review 3.  Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.

Authors:  Emmanuel L Bravo
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 4.  Primary aldosteronism.

Authors:  Richard J Auchus; Fiemu E Nwariaku
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

5.  Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism.

Authors:  Aya T Nanba; Taweesak Wannachalee; James J Shields; James B Byrd; William E Rainey; Richard J Auchus; Adina F Turcu
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

Review 6.  MANAGEMENT OF ENDOCRINE DISEASE: The role of surgical adrenalectomy in primary aldosteronism.

Authors:  Gregory L Hundemer; Anand Vaidya
Journal:  Eur J Endocrinol       Date:  2020-12       Impact factor: 6.664

7.  Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism.

Authors:  Aya T Nanba; Kazutaka Nanba; James B Byrd; James J Shields; Thomas J Giordano; Barbara S Miller; William E Rainey; Richard J Auchus; Adina F Turcu
Journal:  Clin Endocrinol (Oxf)       Date:  2017-09-04       Impact factor: 3.478

8.  Are catecholamine-derived indexes in adrenal venous sampling useful for judging selectivity and laterality in patients with primary aldosteronism?

Authors:  Yasutaka Baba; Sadao Hayashi; Masayuki Nakajo
Journal:  Endocrine       Date:  2012-09-19       Impact factor: 3.633

Review 9.  Primary Aldosteronism: Practical Approach to Diagnosis and Management.

Authors:  James Brian Byrd; Adina F Turcu; Richard J Auchus
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

Review 10.  Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.

Authors:  Laurence Amar; Pierre-François Plouin; Olivier Steichen
Journal:  Orphanet J Rare Dis       Date:  2010-05-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.